OBJECTIVES: Acute myeloid leukemia (AML) is a frequent and highly lethal hematological malignancy that is difficult to treat. The research aimed to clarify the molecular mechanisms of MIR-379-5p in AML progression. MATERIALS AND METHODS: RT-qPCR was utilized to evaluate MIR-379-5p expression levels in AML patients and a control group. A ROC curve was created to assess the clinical predictive value of MIR-379-5p in AML, while cell experiments used CCK-8 assay, flow cytometry, and Transwell chambers. Predicted potential target genes of MIR-379-5p by employing online bioinformatics tools, followed by validation using a dual luciferase reporter assay. RESULTS: MIR-379-5p was significantly decreased in AML patients and had clinical predictive value for the disease. In AML cell lines, MIR-379-5p was down-regulated
conversely, the up-regulation of MIR-379-5p inhibited proliferation, migration, and invasion while promoting apoptosis. Notably, YBX1 was a potential target gene of MIR-379-5p, and its upregulation reduced the effects of MIR-379-5p on AML cell behavior. CONCLUSION: MIR-379-5p had the potential as a biomarker for AML by regulating cell proliferation and apoptosis through targeting YBX1.